Paul Thomas @pgtimmune.bsky.social · 24/11/2025A major challenge is that tumor- and pathogen-specific T cells circulate at extremely low frequencies, often below 1 in 100,000 or even 1 in a million, making them essentially invisible to standard single-cell approaches. 120
Paul Thomas @pgtimmune.bsky.social · 24/11/2025Applying TIRTL-Seq in our FLC vaccine cohort revealed expansive, polyclonal tumor-reactive T cell responses, many shared across patients with common HLA types. This approach exposed public TCR motifs rarely seen in tumor immunity, and mapped the functional landscape of response. 120
Paul Thomas @pgtimmune.bsky.social · 24/11/2025Combining vaccine-induced epitope-specific functional data with TIRTL-Seq repertoire analytics produced a powerful stratification model for clinical response, surpassing standard immune monitoring. 120
